Research programme: cancer therapeutics - BerGenBio

Drug Profile

Research programme: cancer therapeutics - BerGenBio

Alternative Names: BGB 001; BGB 002 target; BGB 003; BGB 109; BGB 10C9; BGB 149; BGB 601; BGB-101

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BerGenBio
  • Class Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Pancreatic cancer

Most Recent Events

  • 28 Feb 2018 BerGenBio plans a clinical trial for BGB 149 Cancer in 2018 (BerGenBio pipeline, February 2018)
  • 10 Mar 2014 BerGenBio receives grant from Research Council of Norway (BIA) for Cancer therapeutic development
  • 05 Feb 2014 Preclinical development is ongoing in Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top